PyInvesting

Market research

DCAL.NSE Dishman Carbogen Amcis Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
27B
P/E ratio
27.9
Analyst target
165
Dividend yield
Not available
Beta
0.62

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

Dishman Carbogen Amcis Limited is currently in a long term uptrend where the price is trading 34.2% above its 200 day moving average.

From a valuation standpoint, the stock is 81.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.

Dishman Carbogen Amcis Limited's total revenue sank by 13.6% to $5B since the same quarter in the previous year.

Its net income has dropped by 148.9% to $-161M since the same quarter in the previous year.

Finally, its free cash flow grew by 2.3% to $2B since the same quarter in the previous year.

Based on the above factors, Dishman Carbogen Amcis Limited gets an overall score of 3/5.